

RXi Pharmaceuticals Corp  
Form 8-K  
June 08, 2018

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d)**

**OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of report (Date of earliest event reported): June 5, 2018**

**RXi PHARMACEUTICALS**

**CORPORATION**

**(Exact name of registrant as specified in its charter)**

<b>Delaware</b>	<b>001-36304</b>	<b>45-3215903</b>
<b>(State or other jurisdiction of</b>	<b>(Commission</b>	<b>(I.R.S. Employer</b>
<b>incorporation or organization)</b>	<b>File Number)</b>	<b>Identification No.)</b>

**257 Simarano Drive, Suite 101**

**Marlborough, Massachusetts 01752**

**(Address of Principal Executive Offices) (Zip Code)**

**Registrant's telephone number, including area code: (508) 767-3861**

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



**Item 5.07. Submission of Matters to a Vote of Security Holders.**

On June 5, 2018, RXi Pharmaceuticals Corporation (the “Company”) held its 2018 Annual Meeting of Stockholders (the “Annual Meeting”). The following items of business were considered and voted upon at the Annual Meeting: (i) election of six director nominees to serve until the 2019 annual meeting; (ii) ratification of the selection of BDO USA, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2018, (iii) an approval of the 2012 RXi Pharmaceuticals Corporation Long Term Incentive Plan, as amended, including an increase in the number of shares available for issuance thereunder, (iv) an approval of an increase in the number of shares available for issuance under the RXi Pharmaceuticals Corporation Employee Stock Purchase Plan, and (v) an approval, for purposes of complying with Nasdaq Listing Rule 5635(d), of the issuance of more than 20% of the Company’s issued and outstanding common stock pursuant to the Purchase Agreement, dated as of August 8, 2017, by and between the Company and Lincoln Park Capital Fund, LLC.

The number of shares of common stock entitled to vote at the Annual Meeting was 4,255,566. The number of shares of common stock present or represented by valid proxy at the annual meeting was 3,267,059. All matters submitted to a binding vote of stockholders at the Annual Meeting were approved. The number of votes cast for and against, and the number of abstentions and broker non-votes with respect to the matters voted upon at the Annual Meeting, are set forth below:

***(i) Election of Directors.***

<b>Director Nominee</b>	<b>Votes For</b>	<b>Votes Withheld</b>
Geert Cauwenbergh, Dr. Med. Sc.	1,326,111	132,232
Robert J. Bitterman	1,371,358	86,985
Keith L. Brownlie	1,372,938	85,405
H. Paul Dorman	1,370,656	87,687
Jonathan E. Freeman, Ph.D.	1,374,867	83,476
Curtis A. Lockshin, Ph.D.	1,374,922	83,421

There were 1,808,716 broker non-votes regarding the election of each director.

***(ii) Ratification of Auditors.***

Stockholders ratified the appointment of BDO USA, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018. The results of the voting were 3,122,294 votes for, 92,997 votes against and 51,768 abstentions. There were no broker non-votes regarding this proposal.

***(iii) An approval of the 2012 RXi Pharmaceuticals Corporation Long Term Incentive Plan, as amended, including an increase in the number of shares available for issuance thereunder.***

Stockholders approved, the 2012 RXi Pharmaceuticals Corporation Long Term Incentive Plan, as amended, including an increase in the number of shares available for issuance thereunder. The results of the voting were 1,255,350 votes for, 173,651 votes against and 29,342 abstentions. There were 1,808,716 broker non-votes regarding this proposal.

***(iv) An approval of an increase in the number of shares available for issuance under the RXi Pharmaceuticals Corporation Employee Stock Purchase Plan.***

Stockholders approved an increase in the number of shares available for issuance under the RXi Pharmaceuticals Corporation Employee Stock Purchase Plan. The results of the voting were 1,259,428 votes for, 171,583 votes against and 27,332 abstentions. There were 1,808,716 broker non-votes regarding this proposal.

***(v) An approval, for purposes of complying with Nasdaq Listing Rule 5635(d), of the issuance of more than 20% of the Company's issued and outstanding common stock pursuant to the Company's purchase agreement with Lincoln Park Capital Fund, LLC.***

Stockholders approved the issuance of more than 20% of the Company's issued and outstanding common stock pursuant to the Company's purchase agreement with Lincoln Park Capital Fund, LLC. The results of the voting were 948,489 votes for, 476,349 votes against and 33,505 abstentions. There were 1,808,716 broker non-votes regarding this proposal.

\* \* \*

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

RXi PHARMACEUTICALS  
CORPORATION

Date: June 8, 2018    By: /s/ Geert Cauwenbergh  
Geert Cauwenbergh, Dr. Med. Sc.

Chief Executive Officer

